The identifier is associated with several distinct official reports and professional records across different sectors. To provide the most helpful summary, please specify which of the following areas you are researching: 1. Pharmaceutical Research (FDA IND 119866)
This is the Investigational New Drug (IND) number for , an interleukin-13 receptor antagonist developed by Dermira Inc. (and later Eli Lilly) for treating moderate-to-severe atopic dermatitis.
Progressed through clinical trials, eventually leading to the FDA-approved product Ebglyss . 119866
A major 119,866-square-foot industrial facility was recently acquired by Chemplast , as reported by Colliers International.
It details findings regarding health services and community consultations for refugees, specifically in the Jordan region. 3. Commercial Real Estate & Market Research The identifier is associated with several distinct official
Targeted as a breakthrough therapy for skin conditions. 2. International Health (UNHCR Document 119866)
"119866" appears in Snohomish County PDS Online Records as a permit number for a closed complaint investigation (Permit 23 119866 CT ). (and later Eli Lilly) for treating moderate-to-severe atopic
This refers to the published by the United Nations High Commissioner for Refugees (UNHCR) in October 2025.